CPA
RXST icon

Capital Performance Advisors’s RxSight RXST Stock Holding History

Capital Performance Advisors’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-53
Closed -$2.62K – 2176
2024
Q3 		$2.62K Buy
+53
New +$2.71K ﹤0.01% 1427

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Capital Performance Advisors's RXST Position: Q4 2024 in Review

Capital Performance Advisors sold out of RxSight (RXST) in Q4 2024, closing a stake of 53 shares — an estimated $2.62K sold.

Capital Performance Advisors first reported a position in RXST in Q3 2024 and held it in 1 quarter. The position peaked at $2.62K in Q3 2024. 212 funds tracked by Wall St. Rank hold RXST as of Q4 2024.

  • Capital Performance Advisors reported no remaining RxSight position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 53 RxSight shares in Q4 2024, an estimated $2.62K.
  • Capital Performance Advisors first reported a position in RxSight in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's RxSight position peaked at $2.62K in Q3 2024.
  • 212 funds tracked by Wall St. Rank held RxSight as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.